Akebia Therapeutics Inc (AKBA)

[PennyMoocher69]

2014 Corporate Highlights

Announced positive top-line results from its Phase 2b study of AKB-6548 in non-dialysis patients with anemia related to CKD
Completed enrollment ahead of schedule in the original two cohorts of its Phase 2 study of AKB-6548 in patients with anemia related to CKD who are undergoing dialysis, and added an additional cohort designed to evaluate the safety, efficacy and tolerability of AKB-6548 dosed three times per week, administered in conjunction with a patient's hemodialysis schedule
Presented data from the AKB-6548 development program at the American Society of Nephrology 2014 Annual Meeting and the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51st Congress
Strengthened corporate leadership with the addition of Brad Maroni, M.D. as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D. as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources
Added Ronald C. Renaud Jr., Michael Clayman, M.D., Maxine Gowen, Ph.D., and Michael Wyzga to the Board of Directors
Completed an initial public offering and fully exercised underwriters' option to purchase additional shares with net proceeds of the offering totaling $104.4 million